

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Michael Kim
312-265-9371
mkim@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

High Tide Inc.

(HITI-NASDAQ)

HITI: F4Q25 Earnings Review – Ongoing Strength Across Financial/Operational KPIs

In USD, HITI reported a net loss of \$33.2 million, or \$(0.39) per share for F4Q25. That said, excluding non-recurring impairment/fair value losses, we put adjusted net income/EPS at essentially breakeven for the quarter compared to our \$0.01 estimate. Higher operating income was offset by less favorable non-operating trends. Lowering our F2026 (Oct) EPS estimate from \$0.12 to \$0.09, and introducing a F2027 estimate of \$0.17. Lowering our price target to \$5.00.

Current Price (1/29/26) **\$2.43**
Valuation **\$5.00**

SUMMARY DATA

52-Week High **\$4.06**
52-Week Low **\$1.64**
One-Year Return (%) **-16.78**
Beta **0.96**
Average Daily Volume (sh) **524,090**

Shares Outstanding (mil) **86**
Market Capitalization (\$mil) **\$208**
Short Interest Ratio (days) **1**
Institutional Ownership (%) **14**
Insider Ownership (%) **12**

Annual Cash Dividend **\$0.00**
Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates
Sales (%) **43.4**
Earnings Per Share (%) **N/A**
Dividend (%) **N/A**

P/E using TTM EPS **N/A**
P/E using 2026 Estimate **27.0**
P/E using 2027 Estimate **14.3**

OUTLOOK

Key F4Q25 takeaways include: 1) High Tide remains the largest cannabis retailer in Canada, with 218 Canna Cabana stores, representing a 12% market share (up from 11% a year ago), and management continues to target opening 20-30 new stores in C2026; 2) Store Sales (SSS) were up 5.5% in F4Q25 and 4.1% for Fiscal 2025; 3) HITI's Cabana Club loyalty program continues to flourish, with 2.5+ million members in Canada, up 45% over the last 12 months and 16% on a sequential quarter basis; 4) paid ELITE membership subscriptions (generating recurring and high-margin revenues) surged by 100%+ year-over-year to 151,000; and 5) assuming the rescheduling of cannabis is enacted, senior management remains focused on bringing the company's Canna Cabana brand, unique discount club model, and related IP/systems/technology to the U.S. likely via licensing agreements with scale-enabled MSOs.

Risk Level **Above Average**
Type of Stock **Small-Blend**
Industry **Medical - Products**

ZACKS ESTIMATES

Revenue
(in millions of \$)

	Q1 (Jan)	Q2 (Apr)	Q3 (Jul)	Q4 (Oct)	Year (Oct)
2024	96 A	91 A	95 A	99 A	376 A
2025	98 A	100 A	108 A	117 A	423 A
2026	129 E	139 E	151 E	160 E	579 E
2027					700 E

Price/Sales Ratio (Industry = 2.5x)

	Q1 (Jan)	Q2 (Apr)	Q3 (Jul)	Q4 (Oct)	Year (Oct)
2024	-\$0.00 A	\$0.00 A	\$0.01 A	-\$0.01 A	\$0.00 A
2025	-\$0.02 A	-\$0.03 A	\$0.01 A	-\$0.39 A	-\$0.45 A
2026	\$0.01 E	\$0.02 E	\$0.03 E	\$0.03 E	\$0.09 E
2027					\$0.17 E

Quarterly revenues/EPS may not equal annual revenues/EPS due to rounding.

F4Q25 EARNINGS REVIEW

After the markets closed on 1/29/26, High Tide reported F4Q25 and full-year F2025 (Oct) earnings results. For the quarter, HITI reported a net loss of \$33.2 million, or \$(0.39) per share compared to our \$0.01 EPS estimate. That said, excluding an impairment charge (e-commerce segment goodwill written off; segment currently accounts for 2% of consolidated revenue) and a fair value change in derivative liability (mostly a function of higher EBITDA forecasts for the Remexian put option), we put adjusted net income at \$0.3 million for the quarter, or essentially breakeven on a per share basis.

Relative to our model, higher operating income (mostly a function of lower-than-forecast operating expense) was offset by less favorable non-operating trends (higher finance costs and FX losses) – Exhibit 1. Focusing on the top line, HITI generated \$116.7 million of revenue in F4Q25, or just ahead of our \$116.1 million forecast. Strong year-over-year and sequential quarter growth primarily reflected accelerating sales of cannabis and CBD products, with same-store sales growth of 5.5% for the quarter. After factoring in cost of sales of \$86.5 million, gross profit totaled \$30.3 million for F4Q25 representing a gross margin of 25.9%, or essentially flat on a year-over-year basis.

In aggregate, HITI's operating expenses totaled \$27.1 million (ex impairments) in F4Q25, down from \$27.7 million in F4Q24, and meaningfully below our \$28.3 million forecast. Much of the favorable variance related to lower salaries, share-based compensation, and interest expenses. Excluding non-cash impairment, loss on fair value change in derivative liability, transaction and acquisition costs, and share-based compensation, Adjusted EBITDA came in at \$8.8 million (7.6% margin) for F4Q25, up from \$5.9 million in the year-ago quarter.

Turning to the balance sheet, cash and cash equivalents totaled C\$47.9 million as of October 31, 2025, essentially unchanged for the year, and down sequentially reflecting the upfront C\$12.3 million payment for Remexian. Looking ahead, management maintains ample liquidity (along with accelerating free cash flows) to fund ongoing new store openings and capitalize on accretive M&A opportunities should they arise.

Exhibit 1: F4Q25 GAAP Actual vs. Estimates
(\$ thousands)

	F4Q25		Change	
	Actual	Estimate	\$	%
Revenue				
Cannabis and CBD products	103,524	103,282	242	0.2%
Consumption accessories	3,910	3,961	(51)	-1.3%
Data analytics, advertising and other revenue	9,315	8,872	443	5.0%
Total Revenue	116,748	116,115	633	0.5%
Cost of Sales	(86,479)	(84,784)	(1,695)	2.0%
Gross Profit	30,269	31,331	(1,062)	-3.4%
Expenses				
Salaries, wages and benefits	(13,391)	(13,954)	563	-4.0%
Share-based compensation	(475)	(639)	164	-25.6%
General and administration	(5,053)	(5,137)	85	-1.7%
Professional fees	(1,900)	(1,785)	(115)	6.4%
Advertising and promotion	(463)	(459)	(4)	0.9%
Depreciation and amortization	(4,628)	(4,716)	88	-1.9%
Impairment loss net of recovery	(16,772)	0	(16,772)	NM
Interest and bank charges	(1,243)	(1,598)	355	-22.2%
Total Expenses	(43,925)	(28,289)	(15,636)	55.3%
Operating Income/(Loss)	(13,656)	3,042	(16,698)	-548.9%
Gain on extinguishment of financial liability	0	0	0	NM
Loss on revaluation of marketable securities	0	0	0	NM
Finance and other costs	(2,772)	(2,278)	(494)	21.7%
Gain on revaluation of put option liability	0	0	0	NM
(Loss) gain on foreign exchange	(237)	0	(237)	NM
Other loss	29	0	29	NM
FV change in derivative liability	(16,737)	0	(16,737)	NM
Gain (loss) on debentures	0	0	0	NM
Pre-Tax Income/(Loss)	(33,373)	764	(34,137)	-4467.4%
Income tax (expense) recovery	(80)	(155)	75	-48.5%
Deferred income tax recovery	206	0	206	NM
Net Income/(Loss)	(33,246)	609	(33,856)	-5555.8%
Earnings per share, diluted	(\$0.39)	\$0.01	(\$0.40)	-5545.7%
Weighted average shares outstanding, basic	85,588	85,429	159	0.2%

Source: Company Reports and Zacks Small Cap Research estimates and calculations.

KEY TAKEAWAYS

Following our review of F4Q25 results, we highlight the following key takeaways:

- 1. Organic growth remains strong:** High Tide remains the largest cannabis retailer in Canada, with 218 Canna Cabana stores across Alberta, Ontario, Saskatchewan, Manitoba, and British Columbia, representing a 12% market share (up from 11% a year ago). The company opened 27 new stores in calendar 2025, and management reiterated guidance of 20-30 new store locations targeted for 2026, with a longer-term goal of operating 350+ locations across Canada. Turning to performance, same Store Sales (SSS) were up 5.5% in F4Q25 and 4.1% for Fiscal 2025. Longer term, SSS increased 151% since the launch of Cabana Club in October 2021 versus a 14% decline for peers on average. From a revenue perspective, Canna Cabana stores in operations for more than six months generated annualized retail sales per square foot of \$1,775 during F4Q25, up 2%+ on a sequential quarter basis (with rising margins and minimal shrinkage rates).
- 2. Cabana Club remains HITI's crown jewel:** Following the launch in 2021, HITI's Cabana Club loyalty program continues to flourish. As of 10/31/25, memberships in Canada exceeded 2.5 million, up 45% over the last 12 months (the highest year-over-year growth rate over the past four quarters) and 16% on a sequential quarter basis, with the company on track to exceed 3 million members over time. Moreover, the number of global memberships rose to 6.56 million as of the end of fiscal 2025, representing year-over-year and sequential-quarter growth rates of 23% and 7%, respectively. In Canada, ELITE membership subscriptions (carrying C\$35 annual fees) surged by 100%+ year-over-year to 151,000 as of 10/31/25. Importantly, ELITE members typically generate higher-dollar receipts with greater frequency, with related membership fees providing a growing source of recurring/high-margin revenues.
- 3. Rescheduling dual-track opportunity:** In mid-December 2025, President Trump issued an executive order instructing the attorney general to expedite the process of rescheduling marijuana to Schedule III of the Controlled Substances Act. Looking ahead, assuming the Drug Enforcement Administration (DEA) publishes a final rule in the Federal Register following Health and Human Services (HHS) scientific and medical evaluations, a public comment period, and potential hearings, we would expect opponent groups to immediately file a "petition for review" and request a "motion to stay" to suspend the effective date. If a judge denies the motion to stay, rescheduling takes effect. That said, if the stay is granted, the ruling remains suspended pending the outcome of related litigation, which could persist for multiple years.

Stepping back, the rescheduling of marijuana from Schedule I to Schedule III potentially paves the way for several key benefits for cannabis-related businesses in the U.S. First, Internal Revenue Code Section 280E would no longer apply, thereby providing for the deduction of business expenses on federal tax returns. Beyond immediate cash flow benefits on a go-forward basis, cannabis companies likely settle outstanding liabilities with the government. Second, marijuana rescheduling likely improves access to banking/financial services for cannabis companies, thereby lowering costs of capital, all else equal. Third, less onerous tax burdens potentially promote stepped-up spending on marketing and/or research and development, thus enhancing sustainable growth across cycles. More broadly, lower regulatory/financial barriers likely spur growth across the industry, with scale-enabled MSOs seemingly well positioned to gain market share, we believe.

Focusing on HITI, management remains focused on bringing the company's Canna Cabana brand, unique discount club model, and related intellectual property/systems/technology to the U.S. likely via licensing agreements with scale-enabled MSOs. We would expect any related partnerships to be highly profitable given limited incremental expenses. Separately, senior officials continue to explore strategic initiatives to more fully leverage the company's NuLeaf Naturals and FAB CBD brands here in the U.S. in light of the inclusion of CBD products under pending pilot programs that provide for up to \$500 per year of CBD products at no cost to the 29+ million Medicare beneficiaries enrolled in private Medicare Advantage plans.

REFINING F2026 EPS ESTIMATE

Our updated model calls for EPS of \$0.09 for F2026 versus our prior forecast of \$0.12 primarily reflecting flatter revenue and gross margin trajectories. Furthermore, we are introducing a F2027 EPS estimate of \$0.17 representing 89% year-over-year growth.

Looking ahead, our model calls for consistent revenue growth through F2026 and beyond. More specifically, we forecast total revenues to rise from \$423 million in F2025 to \$579 million in F2026 and \$700 million in F2027. Our optimism primarily reflects continued organic growth (rising same-store sales and ongoing market share gains), a broader retail store footprint, with the company's store count likely approaching 300 over the next several years (potentially quicker assuming management capitalizes on sizeable M&A blocks coming to market), and accelerating Remexian contributions, particularly as supply chain disruptions in Portugal continue to normalize and the company's distribution footprint expands beyond Germany.

Focusing on Adjusted EBITDA, which excludes transaction costs, other non-recurring items, and stock-based compensation expenses, we forecast a step up in related growth in F2026 fueled in part by ongoing margin expansion. Beyond strong revenue growth, key drivers likely include a step up in gross margins following the sell-through of older/lower-priced product, rising economies of scale, particularly as it relates to incremental headcount needs, ongoing expense management/resource optimization, and accelerating growth across higher-margin initiatives (white label and ELITE memberships). In fact, management reiterated the company's long-term EBITDA margin goal of 12% for HITI's bricks-and-mortar business segment (9.4% in F4Q25).

LOWERING OUR PRICE TARGET TO \$5.00

Turning to valuation, as a result of our lower earnings outlook, we are taking down our DCF-derived price target to \$5.00 – still well above the stock's current levels. Stepping back, absolute/relative performance of most U.S.-based cannabis company stocks remains inextricably linked to the prevailing narrative around regulatory reform in the U.S. In contrast, we look for HITI's strong/improving fundamental story to increasingly resonate with (generalist) investors, thereby driving a material upward revaluation for the stock.

As a crosscheck, we track peer valuation multiples to corroborate our DCF-based price target. To be sure, while apples-to-apples comparisons for cannabis stocks remain challenging given varying regulatory backdrops and growth prospects across countries/states/provinces, not to mention diverging capital, liquidity, and profitability profiles, HITI continues to trade at a discount to most U.S.- and Canadian-based cannabis companies based on Enterprise Value (EV)-to-EBITDA multiples despite what we would argue are well-defined competitive advantages around scale, growth, profitability, and balance sheet metrics, as well as a more favorable regulatory backdrop. In our minds, cannabis companies with steeper growth trajectories, higher revenue throughput, elevated margins, and stronger balance sheets warrant premium valuations, thereby suggesting meaningful upside for HITI assuming a more appropriate multiple.

INVESTMENT THESIS

High Tide is the largest cannabis retailer in Canada operating 200+ stores across Alberta, Ontario, Saskatchewan, British Columbia, and Manitoba. Beyond traditional bricks-and-mortar cannabis stores in Canada (branded Canna Cabana), the company markets Cannabidiol (CBD) and consumption accessories online across Canada, the U.S., the United Kingdom, and Europe. More recently, HITI closed the acquisition of a 51% ownership stake in Remexian Pharma GmbH, a leading low-cost medical cannabis importer/wholesaler in Germany, one of the highest-growth markets in the world, with much of the accelerating demand satisfied through imported cannabis from Canada.

Our investment thesis revolves around:

1. **More favorable regulatory landscape north of the border:** The Cannabis Act and the Cannabis Regulations in 2018 allow for and govern the cultivation/production, processing, retail sale, and distribution of cannabis for both medical and recreational use across Canada. Following the legalization of recreational-use cannabis, Canada has grown into a C\$5.5 billion market, with a majority of sales coming from the five provinces in which High Tide maintains operations.

Turning to the U.S., while HITI's bricks and mortar cannabis sales remain confined to Canada at present, we expect management to increasingly turn their sights south of the border in light of a more favorable regulatory backdrop. As uncertainty around rescheduling probabilities, implications, and timelines fade, we look for cannabis stocks to benefit from enhanced liquidity, rising institutional shareholder ownership profiles, and powerful upward revaluations over time.

2. **Plenty of growth levers to pull:** We look for a powerful step up in HITI's earnings power reflecting the recent majority equity investment in Remexian in Germany, in addition to a number of compelling growth catalysts including: a) strong/sustained Same-Store Sales (SSS) growth; b) ongoing retail store expansion, with management reiterating the company's goal of adding 20-30 new stores this year; c) further step ups in the number of Cabana Club/ELITE loyalty program memberships; d) market shares continuing to roll up to diversified/scale-enabled players; and e) increasingly leveraging white labeling opportunities to further build out the house-branded product portfolio.
3. **Transitioning into a global player:** HITI recently closed the acquisition of a 51% ownership stake in Remexian Pharma GmbH, a leading low-cost medical cannabis importer/wholesaler in Germany. Stepping back, Germany remains amongst the highest-growth markets in the world, particularly following the enactment of the Consumer Cannabis Act in April 2024, which legalized cannabis for medical use. Much of the accelerating demand continues to be satisfied through imported cannabis, particularly from Canada. A key rationale for the transaction was the powerful opportunity to increasingly leverage HITI's procurement expertise and LP network/relationships in Canada to drive accelerating imports/sales in Germany. As such, we see substantial potential for related revenue/EBITDA growth, as HITI increasingly pushes Canadian-supplied cannabis (sourced at lower prices) through Remexian's broad distribution network in Germany.
4. **Building earnings power:** We project a favorable inflection in net income in F2026, with further growth expected in F2027 and beyond as the business continues to scale. Key modeling inputs include accelerating revenue growth reflecting continued organic growth, a broader retail store footprint, and accelerating Remexian contributions, combined with rising margins on the back of building economies of scale, ongoing expense management/resource optimization, and accelerating growth across higher-margin initiatives.
5. **Balance sheet strength:** To be sure, High Tide's strong balance sheet remains a key differentiating factor relative to most other U.S.-based cannabis operators that typically struggle to source capital to fund growth due to regulatory restrictions, with highly-dilutive financings often the only course of action. Put another way, the company maintains ample liquidity and steady free cash flow to fund organic growth initiatives and capitalize on accelerating consolidation trends across the industry should the right opportunities arise. Turning to the liabilities side, High Tide's debt profile remains generally favorable, with long-dated maturities.

INVESTMENT RISKS

- 1. Regulatory uncertainty:** While the distribution and sale of medical and adult-use cannabis, cannabis products, and cannabis accessories is permitted at the Federal level in Canada via legally mandated licenses under the Cannabis Act of 2018, High Tide's business operations along with the company's domestic expansion efforts could be meaningfully impacted by adverse regulatory changes. Furthermore, the company must adhere to inconsistent laws and regulations governing the sale and distribution of cannabis products across the five provinces in which HITI maintains retail locations. Stepping back, any initiatives to enter the U.S. market would require considerable time, resources, and infrastructure to conform related operations to the shifting regulatory framework.
- 2. Rising competition:** The cannabis industry remains highly fragmented, with 3,600+ (and counting) licensed recreational cannabis retail stores across Canada (along with the unregulated illicit market). As such, competition remains fierce, with market shares rolling up to companies that can increasingly leverage high-quality supply, diversified/innovative product sets, broader retail distribution, more cost-effective marketing initiatives, and improving operational efficiencies. While HITI remains amongst the largest cannabis retailers across the provinces in which the company operates, select competitors, particularly scale-enabled, vertically-integrated operators and government wholesalers, may be able to leverage greater financial resources, broader customer relationships, and/or longer operating histories.
- 3. Wholesale pricing volatility:** One of the byproducts of rising competition and oversupply has been pricing pressure, with the price of cannabis directly impacting HITI's revenues, gross profits, and earnings. Furthermore, wholesale pricing remains highly influenced by cultivation conditions, inflationary pressures, the macroeconomic backdrop, shifting demand trends, and/or regulatory changes, with any disruptions in the supply chain likely impairing HITI's economics. That said, wholesale pricing trends in Canada have stabilized more recently, and as a low-cost retailer, HITI is less dependent on pricing to drive revenue growth.
- 4. Reliance on Licensed Producers/government wholesalers:** HITI sales remain dependent on sourcing high-quality cannabis and related products from LPs in a cost-effective manner via government wholesalers. Moreover, proficient supply chain management involves promptly meeting shifting demand trends to minimize related carrying costs. As such, any material disruptions in the cultivation of cannabis products and/or related economics for LPs (including rising costs or less favorable contract terms) could have an adverse effect on HITI's business.
- 5. M&A integration/financing:** Over the years, HITI has completed a number of acquisitions to enhance/extend the company's footprint. All transactions carry meaningful execution and operational risks, particularly assuming accounting/finance, human resources, legal, and other back-office functions are consolidated post-acquisition. Looking ahead, management remains focused on potentially capitalizing on incremental M&A opportunities (at attractive valuations). That said, shareholders likely risk dilution, assuming prospective deals are at least partially financed with equity.

PROJECTED INCOME STATEMENT (CDN)

High Tide Inc.
(CDN in thousands)

	Quarterly								Annual				Y/Y Growth		
	F1Q25	F2Q25	F3Q25	F4Q25	F1Q26E	F2Q26E	F3Q26E	F4Q26E	F2024	F2025	F2026E	F2027E	F2025	F2026E	F2027E
	Jan-25	Apr-25	Jul-25	Oct-25	Jan-26	Apr-26	Jul-26	Oct-26	Oct-24	Oct-25	Oct-26	Oct-27	Oct-25	Oct-26	Oct-27
Revenue															
Cannabis and CBD products	123,619	120,051	131,963	145,451	155,232	169,735	184,783	196,159	452,792	521,084	705,909	863,098	15%	35%	22%
Consumption accessories	7,544	6,415	5,744	5,493	5,383	5,275	5,328	5,382	32,801	25,196	21,368	22,387	-23%	-15%	5%
Data analytics, advertising and other revenue	11,298	11,338	11,983	13,087	13,349	13,482	13,752	14,027	36,713	47,706	54,610	60,596	30%	14%	11%
Total Revenue	142,461	137,804	149,690	164,031	173,964	188,492	203,864	215,567	522,306	593,986	781,887	946,082	14%	32%	21%
Cost of Sales	(107,021)	(102,333)	(109,599)	(121,503)	(129,730)	(140,188)	(151,110)	(159,246)	(379,804)	(440,456)	(580,275)	(696,536)	NM	NM	NM
Gross Profit	35,440	35,471	40,091	42,528	44,233	48,305	52,753	56,321	142,502	153,530	201,612	249,546	8%	31%	24%
Expenses															
Salaries, wages and benefits	(17,581)	(17,476)	(18,288)	(18,814)	(19,953)	(21,431)	(22,975)	(24,078)	(65,082)	(72,159)	(88,438)	(104,729)	NM	NM	NM
Share-based compensation	(1,175)	(1,250)	(824)	(668)	(708)	(768)	(830)	(878)	(2,975)	(3,917)	(3,184)	(3,853)	NM	NM	NM
General and administration	(6,563)	(5,768)	(6,623)	(7,099)	(7,529)	(8,063)	(8,619)	(9,006)	(21,836)	(26,053)	(33,217)	(39,526)	NM	NM	NM
Professional fees	(1,809)	(1,690)	(2,301)	(2,669)	(2,831)	(3,067)	(3,317)	(3,508)	(7,734)	(8,469)	(12,722)	(15,394)	NM	NM	NM
Advertising and promotion	(912)	(1,030)	(592)	(651)	(690)	(748)	(809)	(856)	(4,166)	(3,185)	(3,103)	(3,755)	NM	NM	NM
Depreciation and amortization	(5,847)	(5,880)	(6,080)	(6,503)	(6,897)	(7,473)	(8,082)	(8,546)	(25,393)	(24,310)	(30,998)	(37,507)	NM	NM	NM
Impairment loss net of recovery			0	(23,564)	0	0	0	0	(4,964)	(23,564)	0	0	NM	NM	NM
Interest and bank charges	(1,486)	(1,445)	(1,644)	(1,746)	(2,368)	(2,523)	(2,686)	(2,811)	(5,349)	(6,321)	(10,387)	(12,135)	NM	NM	NM
Total Expenses	(35,373)	(34,539)	(36,352)	(61,714)	(40,976)	(44,073)	(47,319)	(49,682)	(137,499)	(167,978)	(182,050)	(216,899)	NM	NM	NM
Operating Income/(Loss)	67	932	3,739	(19,186)	3,257	4,232	5,435	6,638	5,003	(14,448)	19,562	32,647	-389%	NM	67%
Gain on extinguishment of financial liability	0	0	0	0	0	0	0	0	79	0	0	0	-100%	NM	NM
Gain on extinguishment of put option liability			0	0	0	0	0	0	885	0	0	0	-100%	NM	NM
Loss on revaluation of marketable securities	0	0	0	0	0	0	0	0	(89)	0	0	0	NM	NM	NM
Finance and other costs	(2,731)	(3,566)	(2,676)	(3,895)	(1,285)	(1,285)	(1,285)	(1,285)	(10,058)	(12,868)	(5,140)	(5,140)	NM	NM	NM
Gain on revaluation of put option liability	0	0	0	0	0	0	0	0	657	0	0	0	-100%	NM	NM
(Loss) gain on foreign exchange	13	(114)	(120)	(333)	0	0	0	0	(24)	(554)	0	0	NM	NM	NM
Other loss	0	(42)	1	41	0	0	0	0	(342)	0	0	0	NM	NM	NM
FV change in derivative liability			(43)	(23,516)	0	0	0	0	0	(23,559)	0	0	NM	NM	NM
Gain (loss) on debentures	0	0	0	0	0	0	0	0	(515)	0	0	0	NM	NM	NM
Pre-Tax Income/(Loss)	(2,651)	(2,790)	901	(46,889)	1,972	2,947	4,150	5,354	(4,404)	(51,429)	14,423	27,507	NM	NM	91%
Income tax (expense) recovery	(38)	(46)	(69)	(112)	(394)	(589)	(830)	(1,071)	(601)	(265)	(2,885)	(5,501)	NM	NM	NM
Deferred income tax recovery	0	0	0	290	0	0	0	0	1,194	290	0	0	-76%	-100%	NM
Net Income/(Loss)	(2,689)	(2,836)	832	(46,711)	1,578	2,358	3,320	4,283	(3,811)	(51,404)	11,538	22,006	NM	NM	91%
Translation difference on foreign subsidiary	881	(1,044)	100	514	0	0	0	0	1,591	451	0	0	-72%	-100%	NM
Net comprehensive gain/(loss)	(1,808)	(3,880)	932	(46,197)	1,578	2,358	3,320	4,283	(2,220)	(50,953)	11,538	22,006	NM	NM	91%
Earnings per share, diluted	(\$0.03)	(\$0.04)	\$0.01	(\$0.55)	\$0.02	\$0.03	\$0.04	\$0.05	(\$0.05)	(\$0.62)	\$0.12	\$0.23	NM	NM	89%
Weighted average shares outstanding, basic	80,875	80,936	81,316	85,588	85,802	86,017	86,232	86,447	79,557	82,179	86,124	86,879	3%	5%	1%
Weighted average shares outstanding, diluted			88,578	92,851	93,065	93,279	93,494	93,710			93,387	94,142	NM	NM	1%
Net (loss) Income	(2,689)	(2,836)	832	(46,711)	1,578	2,358	3,320	4,283	(3,811)	(51,404)	11,538	22,006	NM	NM	91%
Income/deferred tax recovery (expense)	38	46	69	(178)	394	589	830	1,071	(593)	(25)	2,885	5,501	NM	NM	91%
Accretion and interest	2,101	1,950	1,795	1,213	1,285	1,285	1,285	1,285	7,444	7,059	5,140	5,140	-5%	-27%	0%
Depreciation and amortization	5,847	5,880	6,080	6,503	6,897	7,473	8,082	8,546	25,393	24,310	30,998	37,507	-4%	28%	21%
EBITDA	5,297	5,040	8,776	(39,173)	10,154	11,705	13,517	15,185	28,433	(20,060)	50,560	70,154	-171%	NM	39%
Foreign exchange loss (gain)	(13)	114	120	333	0	0	0	0	24	554	0	0	2208%	-100%	NM
Transaction and acquisition costs	630	1,616	881	2,682	0	0	0	0	2,614	5,809	0	0	122%	-100%	NM
Loss (gain) revaluation of put option liability	0	0	43	23,516	0	0	0	0	(657)	23,559	0	0	NM	-100%	NM
Other loss (gain)	0	42	(1)	(41)	0	0	0	0	342	0	0	0	-100%	NM	NM
Loss (gain) on extinguishment of debenture	0	0	0	0	0	0	0	0	(885)	0	0	0	NM	NM	NM
Impairment loss	0	0	0	23,564	0	0	0	0	4,964	23,564	0	0	375%	-100%	NM
Share-based compensation	1,175	1,250	824	668	708	768	830	878	2,975	3,917	3,184	3,853	32%	-19%	21%
Loss (gain) on revaluation of marketable securities	0	0	0	865	0	0	0	0	89	865	0	0	872%	-100%	NM
Loss (gain) on revaluation of debenture	0	0	0	0	0	0	0	0	515	0	0	0	-100%	NM	NM
Loss (gain) on extinguishment of financial liability	0	0	0	0	0	0	0	0	(79)	0	0	0	NM	NM	NM
Adjusted EBITDA	7,089	8,062	10,643	12,414	10,862	12,472	14,347	16,063	38,335	38,208	53,744	74,007	0%	41%	38%

Source: Company reports and Zacks SCR estimates and calculations.

PROJECTED INCOME STATEMENT (USD)

High Tide Inc.
(\$ thousands)

	Quarterly								Annual				Y/Y Growth		
	F1Q25	F2Q25	F3Q25	F4Q25	F1Q26E	F2Q26E	F3Q26E	F4Q26E	F2024	F2025	F2026E	F2027E	F2025	F2026E	F2027E
	Jan-25	Apr-25	Jul-25	Oct-25	Jan-26	Apr-26	Jul-26	Oct-26	Oct-24	Oct-25	Oct-26	Oct-27	Oct-25	Oct-26	Oct-27
Revenue															
Cannabis and CBD products	85,296	86,824	95,452	103,524	114,867	125,599	136,735	145,152	325,562	370,878	522,354	638,670	14%	41%	22%
Consumption accessories	5,205	4,639	4,155	3,910	3,983	3,904	3,943	3,982	23,584	17,933	15,812	16,566	-24%	-12%	5%
Data analytics, advertising and other revenue	7,795	8,200	8,668	9,315	9,878	9,976	10,176	10,380	26,397	33,954	40,410	44,840	29%	19%	11%
Total Revenue	98,296	99,663	108,275	116,748	128,728	139,479	150,854	159,514	375,544	422,766	578,575	700,075	13%	37%	21%
Cost of Sales	(73,843)	(74,010)	(79,276)	(86,479)	(95,997)	(103,735)	(111,817)	(117,838)	(273,083)	(313,492)	(429,388)	(515,418)	NM	NM	NM
Gross Profit	24,453	25,653	28,999	30,269	32,732	35,744	39,036	41,676	102,460	109,274	149,188	184,657	7%	37%	24%
Expenses															
Salaries, wages and benefits	(12,131)	(12,639)	(13,228)	(13,391)	(14,765)	(15,858)	(17,001)	(17,817)	(46,795)	(51,359)	(65,442)	(77,497)	NM	NM	NM
Share-based compensation	(811)	(904)	(596)	(475)	(524)	(568)	(614)	(650)	(2,139)	(2,788)	(2,356)	(2,851)	NM	NM	NM
General and administration	(4,528)	(4,172)	(4,791)	(5,053)	(5,571)	(5,967)	(6,378)	(6,664)	(15,700)	(18,543)	(24,580)	(29,248)	NM	NM	NM
Professional fees	(1,248)	(1,222)	(1,664)	(1,900)	(2,095)	(2,270)	(2,455)	(2,596)	(5,561)	(6,028)	(9,414)	(11,391)	NM	NM	NM
Advertising and promotion	(629)	(745)	(428)	(463)	(511)	(554)	(599)	(633)	(2,995)	(2,267)	(2,296)	(2,778)	NM	NM	NM
Depreciation and amortization	(4,034)	(4,253)	(4,398)	(4,628)	(5,103)	(5,530)	(5,981)	(6,324)	(18,258)	(17,302)	(22,938)	(27,754)	NM	NM	NM
Impairment loss net of recovery	0	0	0	(16,772)	0	0	0	0	(3,569)	(16,772)	0	0	NM	NM	NM
Interest and bank charges	(1,025)	(1,045)	(1,189)	(1,243)	(1,752)	(1,867)	(1,988)	(2,080)	(3,846)	(4,499)	(7,686)	(8,980)	NM	NM	NM
Total Expenses	(24,407)	(24,979)	(26,294)	(43,925)	(30,321)	(32,613)	(35,015)	(36,764)	(98,863)	(119,557)	(134,712)	(160,500)	NM	NM	NM
Operating Income/(Loss)	46	674	2,705	(13,656)	2,410	3,132	4,021	4,912	3,597	(10,283)	14,475	24,158	-386%	NM	67%
Gain on extinguishment of financial liability	0	0	0	0	0	0	0	0	57	0	0	0	-100%	NM	NM
Gain on extinguishment of put option liability	0	0	0	0	0	0	0	0	636	0	0	0	-100%	NM	NM
Loss on revaluation of marketable securities	0	0	0	0	0	0	0	0	(64)	0	0	0	NM	NM	NM
Finance and other costs	(1,884)	(2,579)	(1,936)	(2,772)	(951)	(951)	(951)	(951)	(7,232)	(9,159)	(3,803)	(3,803)	NM	NM	NM
Gain on revaluation of put option liability	0	0	0	0	0	0	0	0	472	0	0	0	-100%	NM	NM
(Loss) gain on foreign exchange	9	(82)	(87)	(237)	0	0	0	0	(17)	(394)	0	0	NM	NM	NM
Other loss	0	(30)	1	29	0	0	0	0	(246)	0	0	0	NM	NM	NM
FV change in derivative liability	0	0	(31)	(16,737)	0	0	0	0	0	(16,768)	0	0	NM	NM	NM
Gain (loss) on debentures	0	0	0	0	0	0	0	0	(370)	0	0	0	NM	NM	NM
Pre-Tax Income/(Loss)	(1,829)	(2,018)	652	(33,373)	1,459	2,181	3,071	3,962	(3,167)	(36,604)	10,672	20,355	NM	NM	91%
Income tax (expense) recovery	(26)	(33)	(50)	(80)	(292)	(436)	(614)	(792)	(432)	(189)	(2,134)	(4,071)	NM	NM	NM
Deferred income tax recovery	0	0	0	206	0	0	0	0	858	206	0	0	-76%	-100%	NM
Net Income/(Loss)	(1,855)	(2,051)	602	(33,246)	1,167	1,745	2,457	3,169	(2,740)	(36,586)	8,538	16,284	NM	NM	91%
Translation difference on foreign subsidiary	608	(755)	72	366	0	0	0	0	1,144	321	0	0	-72%	-100%	NM
Net comprehensive gain/(loss)	(1,247)	(2,806)	674	(32,880)	1,167	1,745	2,457	3,169	(1,596)	(36,265)	8,538	16,284	NM	NM	91%
Earnings per share, diluted															
	(\$0.02)	(\$0.03)	\$0.01	(\$0.39)	\$0.01	\$0.02	\$0.03	\$0.03	(\$0.03)	(\$0.45)	\$0.09	\$0.17	NM	NM	89%
Weighted average shares outstanding, basic	80,875	80,936	81,316	85,588	85,802	86,017	86,232	86,447	79,557	82,179	86,124	86,879	3%	5%	1%
Weighted average shares outstanding, diluted			88,578	92,851	93,065	93,279	93,494	93,710			93,387	94,142	NM	NM	1%
Net (loss) Income															
	(1,855)	(2,051)	602	(33,246)	1,167	1,745	2,457	3,169	(2,740)	(36,586)	8,538	16,284	NM	NM	91%
Income/deferred tax recovery (expense)	26	33	50	(127)	292	436	614	792	(426)	(18)	2,134	4,071	NM	NM	91%
Accretion and interest	1,450	1,410	1,298	863	951	951	951	951	5,352	5,024	3,803	3,803	-6%	-24%	0%
Depreciation and amortization	4,034	4,253	4,398	4,628	5,103	5,530	5,981	6,324	18,258	17,302	22,938	27,754	-5%	33%	21%
EBITDA	3,655	3,645	6,348	(27,881)	7,514	8,661	10,002	11,236	20,444	(14,278)	37,413	51,912	-170%	NM	39%
Foreign exchange loss (gain)	(9)	82	87	237	0	0	0	0	17	394	0	0	2185%	-100%	NM
Transaction and acquisition costs	435	1,169	637	1,909	0	0	0	0	1,879	4,135	0	0	120%	-100%	NM
Loss (gain) revaluation of put option liability	0	0	31	16,737	0	0	0	0	(472)	16,768	0	0	NM	-100%	NM
Other loss (gain)	0	30	(1)	(29)	0	0	0	0	246	0	0	0	-100%	NM	NM
Loss (gain) on extinguishment of debenture	0	0	0	0	0	0	0	0	(636)	0	0	0	NM	NM	NM
Impairment loss	0	0	0	16,772	0	0	0	0	3,569	16,772	0	0	370%	-100%	NM
Share-based compensation	811	904	596	475	524	568	614	650	2,139	2,788	2,356	2,851	30%	-15%	21%
Loss (gain) on revaluation of marketable securities	0	0	0	616	0	0	0	0	64	616	0	0	862%	-100%	NM
Loss (gain) on revaluation of debenture	0	0	0	0	0	0	0	0	370	0	0	0	-100%	NM	NM
Loss (gain) on extinguishment of financial liability	0	0	0	0	0	0	0	0	(57)	0	0	0	NM	NM	NM
Adjusted EBITDA	4,891	5,831	7,698	8,836	8,038	9,229	10,616	11,886	27,563	27,194	39,769	54,763	-1%	46%	38%

Source: Company reports and Zacks SCR estimates and calculations.


PROJECTED BALANCE SHEET (CDN)

High Tide Inc.
(CDN in thousands)

	Quarterly								Annual				Y/Y Growth		
	F1Q25	F2Q25	F3Q25	F4Q25	F1Q26E	F2Q26E	F3Q26E	F4Q26E	F2024	F2025	F2026E	F2027E	F2025	F2026E	F2027E
	Jan-25	Apr-25	Jul-25	Oct-25	Jan-26	Apr-26	Jul-26	Oct-26	Oct-24	Oct-25	Oct-26	Oct-27	Oct-25	Oct-26	Oct-27
Assets															
Current Assets:															
Cash and cash equivalents	33,341	34,692	63,809	47,883	48,362	48,845	49,334	49,827	47,267	47,883	49,827	51,820	1%	4%	4%
Marketable securities	712	303	64	64	65	67	68	69	712	64	69	75	-91%	8%	8%
Trade and other receivables	3,463	2,752	3,551	5,615	5,727	5,842	5,959	6,078	3,308	5,615	6,078	6,564	70%	8%	8%
Inventory	30,397	28,226	31,258	67,406	68,754	70,129	71,532	72,962	29,338	67,406	72,962	78,799	130%	8%	8%
Prepaid expenses and deposits	5,819	8,062	4,920	15,917	16,235	16,560	16,891	17,229	5,164	15,917	17,229	18,607	208%	8%	8%
Total Current Assets	73,732	74,035	103,602	136,885	139,144	141,443	143,784	146,166	85,789	136,885	146,166	155,866	60%	7%	7%
Non-Current Assets:															
Property and equipment	28,173	28,496	28,539	29,436	30,025	30,625	31,238	31,862	27,471	29,436	31,862	34,411	7%	8%	8%
Right-of-use assets	37,661	35,565	35,563	47,793	48,749	49,724	50,718	51,733	36,525	47,793	51,733	55,871	31%	8%	8%
Long term prepaid expenses and deposits	3,630	3,325	3,225	5,399	5,507	5,617	5,729	5,844	3,607	5,399	5,844	6,312	50%	8%	8%
Intangible assets and goodwill	92,467	90,559	89,460	129,549	126,958	124,419	121,930	119,492	92,816	129,549	119,492	109,933	40%	-8%	-8%
Total Non-Current Assets	161,931	157,945	156,787	212,177	211,239	210,385	209,616	208,931	160,419	212,177	208,931	206,527	32%	-2%	-1%
Total Assets	235,663	231,980	260,389	349,062	350,382	351,828	353,400	355,097	246,208	349,062	355,097	362,393	42%	2%	2%
Liabilities															
Current Liabilities:															
Accounts payables and accrued liabilities	21,893	22,112	21,829	47,251	47,724	48,201	48,683	49,170	22,150	47,251	49,170	51,136	113%	4%	4%
Income tax payable		1,691	1,603	7,189	7,189	7,189	7,189	7,189	1,659	7,189	7,189	7,189	333%	0%	0%
Deferred revenue	1,838	2,552	5,931	7,989	7,989	7,989	7,989	7,989	1,990	7,989	7,989	7,989	301%	0%	0%
Interest bearing loans and borrowings	11,997	11,052	10,087	16,189	15,865	15,548	15,237	14,932	12,891	16,189	14,932	13,738	26%	-8%	-8%
Current portion of notes payable	724	279	0	1,536	1,536	1,536	1,536	1,536	13,974	1,536	1,536	1,536	-89%	0%	0%
Convertible debentures			0	0	0	0	0	0	0	0	0	0	NM	NM	NM
Current portion of lease liabilities	9,376	9,502	9,746	9,814	9,912	10,011	10,111	10,212	8,816	9,814	10,212	10,621	11%	4%	4%
Put option/derivative liability			6,863	9,951	9,951	9,951	9,951	9,951	0	9,951	9,951	9,951	NM	0%	0%
Total Current Liabilities	45,828	47,188	56,059	99,919	100,166	100,425	100,696	100,979	61,480	99,919	100,979	102,160	63%	1%	1%
Non-Current Liabilities:															
Notes payable	68	66	66	11,903	11,903	11,903	11,903	11,903	65	11,903	11,903	11,903	18212%	0%	0%
Lease liabilities	32,328	30,307	30,252	39,986	40,386	40,790	41,198	41,610	31,391	39,986	41,610	43,274	27%	4%	4%
Deferred tax liability	285	292	290	7,100	7,171	7,243	7,315	7,388	284	7,100	7,388	7,684	2400%	4%	4%
Secured Debentures	12,054	12,214	12,308	12,536	12,661	12,788	12,916	13,045	7,476	12,536	13,045	13,567	68%	4%	4%
Derivative liability				56,954	56,954	56,954	56,954	56,954		56,954	56,954	56,954			
Convertible Debt			17,923	17,877	17,519	17,169	16,826	16,489		17,877	16,489	15,170	NM	-8%	-8%
Total Non-Current Liabilities	44,735	42,879	60,839	146,356	146,595	146,846	147,111	147,389	39,216	146,356	147,389	148,552	273%	1%	1%
Total Liabilities	90,563	90,067	116,898	246,275	246,761	247,271	247,807	248,368	100,696	246,275	248,368	250,712	145%	1%	1%
Total Shareholders' Equity	145,100	141,913	143,491	102,787	103,622	104,557	105,592	106,729	145,512	102,787	106,729	111,681	-29%	4%	5%
Total Liabilities & Shareholders' Equity	235,663	231,980	260,389	349,062	350,382	351,828	353,400	355,097	246,208	349,062	355,097	362,393	42%	2%	2%

Source: Company reports and Zacks SCR estimates and calculations.

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, @AnalystName, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article. Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.